Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on innovative cardiovascular treatments, has announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston. The company's Chief Financial Officer, Amit Hasija, and Chief Commercial Officer, Lorenz Muller, will be presenting at the event. The slated presentation is set for March 3rd at 9:10 AM EST, and it will be available via a live webcast. Interested parties can also access a replay of the presentation for approximately 90 days following the event on Milestone's website, www.milestonepharma.com.

Milestone Pharmaceuticals is particularly known for its lead product, CARDAMYST™ (etripamil) nasal spray, which is an innovative calcium channel blocker. This product has received FDA approval for treating acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults. Additionally, the company is advancing the development of etripamil for symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular response (AFib-RVR).

The TD Cowen conference offers Milestone an opportunity to connect with investors and stakeholders to discuss its progress, future plans, and the potential of its groundbreaking therapies. For those interested in scheduling meetings with Milestone representatives during the conference, it is recommended to coordinate through TD Cowen representatives.

Overall, Milestone's participation in this prominent healthcare event highlights its commitment to advancing cardiovascular care and engaging with the financial community, as it seeks to address the needs of patients with specific heart conditions.

As Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) prepares to present at the TD Cowen 46th Annual Health Care Conference, investors should closely monitor developments and insights shared during this event. Milestone, known for its innovative cardiovascular medicines, has been positioning itself strategically within the biopharmaceutical landscape, particularly with its flagship product, CARDAMYST™ (etripamil), which offers a novel solution for treating paroxysmal supraventricular tachycardia (PSVT).

Investors should consider a few critical factors as they assess Milestone's market potential. First, the recent FDA approval of etripamil for PSVT enhances the company's credibility and market reach. Its ongoing development for treating symptomatic attacks associated with AFib-RVR could further bolster revenue potential and diversify the product pipeline, positioning Milestone as a key player in the cardiovascular space.

Attending the TD Cowen Conference is an excellent opportunity for Milestone's leadership to connect with investors and analysts, potentially leading to increased interest in the stock. Stakeholders should watch this presentation closely, particularly regarding any updates on commercial launch strategies, clinical trial progress, and partnerships that could accelerate market penetration.

From a tactical standpoint, investors might consider initiating or adjusting their positions in Milestone ahead of the conference. If the presentation highlights positive clinical outcomes or strong market adoption strategies, there could be upward momentum in share prices. Conversely, if the dialogue centers on challenges or slow uptake, this could result in downward pressure on the stock.

In summary, Milestone Pharmaceuticals presents a compelling investment opportunity within the biopharmaceutical sector, particularly for those focused on innovative cardiovascular therapies. Staying informed through the conference is essential for making data-driven decisions in this volatile market.